Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection

Clinical Infectious Diseases

Volumn 50, Issue 1, 2010, Pages 98-105

  Gill, Vikram S ^a   Lima, Viviane D ^a   Zhang, Wen ^a   Wynhoven, Brian ^a   Yip, Benita ^a   Hogg, Robert S ^a,b   Montaner, Julio S G ^a   Harrigan, P Richard ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b SIMON FRASER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ARTICLE; CANADA; DRUG EFFICACY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS ISOLATION; VIRUS LOAD; VIRUS RESISTANCE;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRITISH COLUMBIA; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; PROTEASE INHIBITORS; REGRESSION ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 72049086981     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/648729     Document Type: Article

References (15)

1. Hogg RS, Yip B, Kully C, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ 1999; 160:659-665 (Pubitemid 29149796)
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodefi- ciency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860
3. Santoro MM, Ciccozzi M, Alteri C, et al. Characterization of drugresistance mutations in HIV type 1 isolates from drug-naive and ARVtreated patients in Bulgaria. AIDS Res Hum Retroviruses 2008; 24: 1133-1138
4. Panos G, Charatsis G, Paparizos V, Kazantzi M, Falagas ME. Prevalence of genotypic resistance to nucleoside analogues, nonnucleoside analogues, and protease inhibitors in HIV-infected persons in Athens, Greece. AIDS Res Hum Retroviruses 2008; 24:43-51.
5. Escoto-Delgadillo M, Vazquez-Valls E, Ramirez-Rodriguez M, et al. Drug-resistance mutations in antiretroviral-naive patients with established HIV-1 infection in Mexico. HIV Med 2005; 6:403-409 (Pubitemid 41723308)
6. Richman DD, Morton SC,Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004; 18:1393-1401 (Pubitemid 38925131)
7. von Wyl V, Yerly S, Böni J, et al. Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. Clin Infect Dis 2009; 48:979-987
8. Costagliola D, Descamps D, Assoumou L, et al. Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study. J Acquir Immune Defic Syndr 2007; 46:12-18 (Pubitemid 47507429)
9. Vercauteren J, Deforche K, Theys K, et al. The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal. Retrovirology 2008; 5:12.
10. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286:2568-2577 (Pubitemid 33096808)
11. Cheung PK, Wynhoven B, Harrigan PR. 2004: Which HIV-1 drug resistance mutations are common in clinical practice? AIDS Rev 2004; 6:107-116
12. Hogg RS, Bangsberg DR, Lima VD, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 2006; 3:e356.
13. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 191:339-347
14. Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47:266-285
15. Brumme ZL, Brumme CJ, Heckerman D, et al. Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog 2007; 3:e94.